2023
Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes
Sauta E, Zampini M, Dall'Olio D, Sala C, Todisco G, Travaglino E, Lanino L, Tentori C, Maggioni G, D'Amico S, Asti G, Dall'Olio L, Mosca E, Ubezio M, Campagna A, Riva E, Bicchieri M, Savevski V, Santoro A, Kordasti S, Santini V, Diez-Campelo M, Kubasch A, Platzbecker U, Fenaux P, Zhao L, Zeidan A, Haferlach T, Castellani G, Della Porta M. Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes. Blood 2023, 142: 1863. DOI: 10.1182/blood-2023-186222.Peer-Reviewed Original ResearchAcute myeloid leukemiaProportional hazards modelOverall survivalClinical outcomesMyelodysplastic syndromeClinical featuresMDS patientsPrognostic informationConcordance indexCox proportional hazards modelConventional prognostic scoresIPSS-R scorePrimary end pointBone marrow blastsHarrell's concordance indexPeripheral blood cytopeniasPrognostic scoring systemRisk of progressionAdditional prognostic informationCytogenetic alterationsGene mutationsIndividual patient levelSame clinical phenotypeBlood cytopeniasMarrow blasts
2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review Of Hematology 2017, 10: 345-364. PMID: 28277851, DOI: 10.1080/17474086.2017.1297704.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsErythropoiesis stimulating agentsMyelodysplastic syndromeLR-MDSImmunosuppressive therapyTreatment modalitiesLower-risk myelodysplastic syndromesTGF-β pathway inhibitorCombination treatment modalitiesLR-MDS patientsPromising investigational agentsSubset of patientsAvailable therapeutic modalitiesGoals of careStandard therapeutic optionPredictors of responseCurrent treatment modalitiesAcute myeloid leukemiaQuality of lifeBone marrow failureRisk assessment toolSymptom controlBlood cytopeniasInvestigational agentsTherapeutic optionsClinical behaviorLenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications
Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer 2017, 123: 1703-1713. PMID: 28192601, DOI: 10.1002/cncr.30585.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaProlong survivalLow-risk MDSLR-MDS patientsEfficacy of lenalidomideImpressive clinical activityRecent clinical dataClonal myeloid neoplasmsMechanism of actionBlood cytopeniasConventional careTransfusion independenceCytogenetic responseClinical activityMyeloid leukemiaClinical dataIneffective hematopoiesisMyeloid neoplasmsDelay progressionHigh riskLenalidomidePatientsVariable riskHeterogeneous groupProgression
2016
Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016
Zeidan AM, Battiwalla M, Berlyne D, Winkler T. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. Leukemia Research 2016, 53: 8-12. PMID: 27923195, PMCID: PMC7731993, DOI: 10.1016/j.leukres.2016.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow failure syndromesMDS International FoundationAplastic anemiaPeripheral blood cytopeniasAcute myelogenous leukemiaMarrow failure syndromesBlood cytopeniasCommon manifestationIneffective hematopoiesisMyelogenous leukemiaFailure syndromeClinical implicationsHematopoietic stem cell compartmentStem cell compartmentPatientsAnemiaCell compartmentFamily membersIndependent nonprofit organizationInternational FoundationCytopeniasSyndromePathogenesisLeukemia
2014
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
Zahr A, Aldin E, Komrokji RS, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal Of Blood Medicine 2014, Volume 6: 1-16. PMID: 25565910, PMCID: PMC4278786, DOI: 10.2147/jbm.s50482.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyelodysplastic syndromeClinical trialsClinical utilityRed blood cell transfusion requirementsLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeActivity of lenalidomideDifferent prognostic scoresMajor clinical trialsPeripheral blood cytopeniasEfficacy of lenalidomideClonal hematopoietic disordersQuality of lifeMechanism of actionMDS managementTransfusion requirementsBlood cytopeniasPrognostic scoreClinical outcomesRisk stratificationMechanisms of resistanceIneffective hematopoiesisLenalidomideDrug lenalidomideLeukemic transformation